When Vera Therapeutics released initial mid-stage data on its immunoglobulin A nephropathy (IgAN) project atacicept in January investors were disappointed with an apparently uncompetitive reduction in proteinuria at 24 weeks. Now comes better news.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,